Keith Eaton
Associate Professor
Medicine
Fred Hutchinson Cancer Rearch Center
United States of America
Biography
Keith D. Eaton, MD is a practicing Oncologist in Seattle, WA. Dr. Eaton graduated from University of California San Diego School of Medicine in 1998 and has been in practice for 23 years. Dr. Eaton also specializes in Internal Medicine. He currently practices at Seattle Cancer Care Alliance and is affiliated with Harborview Medical Center and University of Washington Medical Center. Dr. Eaton accepts multiple insurance plans including Aetna, First Choice Health and Medicare. Dr. Eaton is board certified in Medical Oncology and Internal Medicine. Dr. Eaton also practices at University of Washington Medical Center in Seattle, WA. In addition to English, Dr. Eaton's practice supports these languages: German, Spanish and French.
Research Interest
Clinical Trials, Supportive Care
Publications
-
Eaton, K. D., Jagels, B., & Martins, R. G. (2016). Value-based care in lung cancer. The oncologist, 21(8), 903-906.
-
Ou, S. H. I., Govindan, R., Eaton, K. D., Otterson, G. A., Gutierrez, M. E., Mita, A. C., ... & Ho, S. N. (2017). Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non–small cell lung cancer. Journal of Thoracic Oncology, 12(1), 145-151.
-
Chow, L. Q., Morishima, C., Eaton, K. D., Baik, C. S., Goulart, B. H., Anderson, L. N., ... & Disis, M. L. (2017). Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clinical Cancer Research, 23(10), 2442-2450.
-
Pellini Ferreira, B., Redman, M., Baker, K. K., Martins, R., Eaton, K. D., Chow, L. Q. M., ... & Rodriguez, C. P. (2017). Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. The Laryngoscope, 127(7), 1583-1588.
-
Awad, M. M., Chu, Q. S., Gandhi, L., Stephenson, J. J., Govindan, R., Bradford, D. S., ... & Munzert, G. (2017). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer, 104, 126-130.
